Unjha Formulations Reports Positive Financial Results for Q2 2024, Stock Receives 'Hold' Call.

Unjha Formulations, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financial report, Unjha Formulations has shown positive performance in the second quarter of the fiscal year 2024-2025. The company's score has improved from 15 to 6 in the last three months.

One of the key highlights of the financial report is the increase in Profit After Tax (PAT) for the half-yearly period. The company has recorded a PAT of Rs 0.59 crore, which is higher than the previous 12-month period ending in September 2024. This indicates a strong growth in the company's profitability.

Another positive aspect of the financial report is the increase in Operating Cash Flow for the year. Unjha Formulations has generated a cash flow of Rs 1.03 crore, which is the highest in the last three years. This shows that the company has been able to generate higher revenues from its business operations.

However, there are also some areas that need improvement for Unjha Formulations. The company's Operating Profit (PBDIT) for the quarter is the lowest in the last five quarters, standing at Rs -0.11 crore. This indicates a negative trend in the near term.

Similarly, the Profit Before Tax less Other Income (PBT) for the quarter is also the lowest in the last five quarters, at Rs -0.13 crore. This shows a negative trend in the near term for the company's profitability.

Overall, Unjha Formulations has shown a positive financial performance in the second quarter of the fiscal year 2024-2025. However, there are some areas that need improvement in the near term. Investors are advised to hold their position in the company's stock, as recommended by MarketsMOJO.